Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Childhood Malignant Solid Neoplasm

Tundra lists 2 Childhood Malignant Solid Neoplasm clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06915727

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Pafolacianine is a fluorescent imaging agent that targets folate receptors which are overexpressed in many cancers and is used with near infrared (NIR) imaging during surgery to identify tumor cells. NIR uses a special camera that uses wavelengths in the infrared range to visualize and locate the tumor cells that are lit up by the pafolacianine. Giving pafolacianine for NIR imaging may work better than other imaging agents in identifying cancerous lesions in pediatric patients with solid tumors.

Gender: All

Ages: 6 Months - 17 Years

Updated: 2026-04-01

1 state

Childhood Malignant Solid Neoplasm
Childhood Malignant Thoracic Neoplasm
Malignant Abdominal Neoplasm
+3
NOT YET RECRUITING

NCT07412002

Quality of End-of-Life Care for Children With Cancer

This study examines the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in quality of end of life care. The data collected from this study may help researchers develop a model for identifying patients at risk of low quality end of life care as well as recommendations for potential future interventions.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-13

Childhood Hematopoietic and Lymphatic System Neoplasm
Childhood Malignant Solid Neoplasm